Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gilead Sciences Inc 333 LAKESIDE DRIVE FOSTER CITY CA 94404 USA

www.gilead.com Employees: 17,600 P: 650-574-3000 F: 650-522-5853

Sector:

Medical

Description:

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Key Statistics

Overview:

Market Capitalization, $K 155,916,256
Enterprise Value, $K 173,931,264
Shares Outstanding, K 1,240,680
Annual Sales, $ 28,754 M
Annual Net Income, $ 480,000 K
Last Quarter Sales, $ 7,769 M
Last Quarter Net Income, $ 3,052 M
EBIT, $ 10,490 M
EBITDA, $ 13,257 M
60-Month Beta 0.32
% of Insider Shareholders 0.27%
% of Institutional Shareholders 83.67%
Float, K 1,237,330
% Float 99.73%
Short Interest 18,480
Short Float 1.49%
Short Volume Ratio 0.56

Growth:

1-Year Return 33.76%
3-Year Return 46.38%
5-Year Return 115.71%
5-Year Revenue Growth 28.09%
5-Year Earnings Growth -24.76%
5-Year Dividend Growth 22.22%

Per-Share Information:

Most Recent Earnings 2.47 on 10/30/25
Next Earnings Date 02/10/26
Earnings Per Share ttm 8.19
EPS Growth vs. Prev Qtr 22.89%
EPS Growth vs. Prev Year 22.28%
Annual Dividend & Yield 3.16 (2.51%)
Annual Dividend & Yield (Fwd) 3.16 (2.52%)
Most Recent Dividend 0.790 on 12/15/25
Next Ex-Dividends Date 12/15/25
Dividend Payable Date 12/30/25
Dividend Payout Ratio 37.96%
Most Recent Split 2-1 on 01/28/13

GILD Ratios

Ratio
Price/Earnings ttm 15.29
Price/Earnings forward 15.33
Price/Earnings to Growth 0.69
Return-on-Equity % 51.86%
Return-on-Assets % 17.92%
Profit Margin % 1.67%
Debt/Equity 1.16
Price/Sales 5.40
Price/Cash Flow 18.22
Price/Book 7.24
Book Value/Share 17.29
Interest Coverage -1.71

GILD Dividends

Date Value
12/15/25 $0.7900
09/15/25 $0.7900
06/13/25 $0.7900
03/14/25 $0.7900
12/13/24 $0.7700
09/13/24 $0.7700
06/14/24 $0.7700
03/14/24 $0.7700
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar